Hrustanovic, Gorjan, and Tanizaki, J et al. [85, 86] found that EML4-ALK fusion NSCLC cells specifically depend on the MAPK pathway, and their sensitivity to MEK inhibitors is similar to that of KRAS or BRAF-positive lung adenocarcinoma cells. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.